Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke
Stroke 38:85-89, Ehlers,L.,et al, 2007
Estimated Cost Savings of Increased Use of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Canada
Storke 38:1952-1955,1732, Yip,T.R. &Demaerschalk,B.M., 2007
Long-Term Outcome After Thrombolysis in Telemedical Stroke Care
Neurol 69:898-903,819, Schwab,S.,et al, 2007
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States
Stroke 36:2500-2503, Demaerschalk,B.M. &Yip,T.R., 2005
MERCI 1, A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia
Stroke 35:2848-2854, Gobin,Y.P.,et al, 2004
Diagnosis and Treatment of Ischemic Stroke
Am J Med 106:211-221, Alberts,M.J., 1999
Treatment and Secondary Prevention of Stroke:Evidence, Costs, and Effects on Individuals and Populations
Lancet 354:1457-1463, Hankey,G.J.&Warlow,C.P., 1999
Predictors of Clinical Improvement,Angiographic Recanalization, and Intracranial Hemorrhage After Intra-Arterial Thrombolysis for Acute Ischemic Stroke
Stroke 30:2094-2100, Suarez,J.I.,et al, 1999
Early Intravenous Thrombolysis for Acute Ischemic Stroke in a Community-Based Approach
Stroke 29:1544-1549, Grond,M.,et al, 1998
Cost-Effectiveness of Tissue Plasminogen Activator for Acute Ischemic Stroke
Neurol 50:883-890, Fagan,S.C.,et al, 1998